In this interview, Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, gives his forecast of the acute myeloid leukemia (AML) data to look forward to in 2018 and beyond. Dr Stone highlights key data due to be release in 2018 for the trials of the second-generation FLT3 inhibitors quizartinib and gilteritinib vs. standard chemotherapy in advanced FLT3-mutated AML. He also anticipates the results of several significant venetoclax trials for AML. Furthermore, he discusses the immunotherapies to look out for, including antibody-drug conjugates, BiTES and DARTs. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
AML: data to look forward to in 2018 and beyond
